BidaskClub upgraded shares of NantHealth (NASDAQ:NH) from a strong sell rating to a sell rating in a report published on Tuesday morning.
Several other research analysts have also recently weighed in on the company. Zacks Investment Research cut NantHealth from a buy rating to a hold rating in a research note on Wednesday, October 25th. Canaccord Genuity decreased their price target on NantHealth from $6.00 to $5.00 and set a buy rating for the company in a research note on Friday, November 17th. Finally, Jefferies Group restated a buy rating and issued a $5.00 price target on shares of NantHealth in a research note on Thursday, September 28th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $8.05.
NantHealth (NASDAQ NH) traded up $0.01 during mid-day trading on Tuesday, hitting $3.77. The stock had a trading volume of 194,612 shares, compared to its average volume of 157,598. NantHealth has a 52-week low of $2.60 and a 52-week high of $10.19. The company has a quick ratio of 2.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $407.32, a PE ratio of -2.12 and a beta of -1.50.
Institutional investors have recently bought and sold shares of the stock. Alliancebernstein L.P. purchased a new stake in NantHealth during the second quarter valued at $102,000. GSA Capital Partners LLP purchased a new stake in NantHealth during the second quarter valued at $121,000. Teachers Advisors LLC increased its position in NantHealth by 351.8% in the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock worth $134,000 after buying an additional 24,588 shares in the last quarter. California State Teachers Retirement System increased its position in NantHealth by 132.4% in the second quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock worth $134,000 after buying an additional 18,000 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. purchased a new stake in NantHealth in the third quarter worth about $180,000. Institutional investors own 7.10% of the company’s stock.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.